FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Robert Buchanan

Research Profile

Disorders

Activities & Behaviors

Schizophrenic Psychology

Chemicals & Drugs

Concepts & Ideas

Procedures

Anatomy

Brain

Physiology

Attention

Co-author Network

Publications

TOP 3
Gregory Strauss; Robert W Buchanan; Bernard A IV Fischer; Michael F Green; William P Horan; William R Keller; Brian Kirkpatrick; Pinar Miski; William T Carpenter
Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome.
Daniel N Allen; Kimberly A Barchard; William T Carpenter; Gregory Strauss; Mary Vertinski; Robert W Buchanan
Differences in developmental changes in academic and social premorbid adjustment between males and females with schizophrenia.
Mary R Lee; Jared Linthicum; Fang Liu; Robert P McMahon; Gregory Strauss; Heidi Wehring; Alan S Bellack; Robert W Buchanan; Nicola G Cascella; Carlo Contoreggi; Deanna L Kelly
Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Robert Buchanan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Gregory Strauss; Robert W Buchanan; Bernard A IV Fischer; Michael F Green; William P Horan; William R Keller; Brian Kirkpatrick; Pinar Miski; William T Carpenter
Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome.
Journal of psychiatric research 2013;47(6):783-90.
2013: Daniel N Allen; Kimberly A Barchard; William T Carpenter; Gregory Strauss; Mary Vertinski; Robert W Buchanan
Differences in developmental changes in academic and social premorbid adjustment between males and females with schizophrenia.
Schizophrenia research 2013;146(1-3):132-7.
2013: Mary R Lee; Jared Linthicum; Fang Liu; Robert P McMahon; Gregory Strauss; Heidi Wehring; Alan S Bellack; Robert W Buchanan; Nicola G Cascella; Carlo Contoreggi; Deanna L Kelly
Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study.
Schizophrenia research 2013;145(1-3):110-5.
2013: William R Keller; Maju Mathew Koola; Lionel M Kum; Heidi Wehring; Robert W Buchanan; Deanna L Kelly
A review of anti-inflammatory agents for symptoms of schizophrenia.
Journal of psychopharmacology (Oxford, England) 2013;27(4):337-42.
2013: Richard S E Keefe; Stephen R Marder; Nina R Schooler; Robert W Buchanan; Ashish Dugar; Milana Zivkov; Michelle Stewart
Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?
Schizophrenia bulletin 2013;39(2):417-35.
2013: Kimberly R Warren; Jared Linthicum; Fang Liu; Robert P McMahon; M Patricia Ball; Robert W Buchanan; Robert R Conley; Stephanie Feldman; David A Gorelick; Marilyn A Huestis; Deanna L Kelly
Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.
Journal of clinical psychopharmacology 2013;33(1):118-20.
2013: Britta Hahn; James M Gold; Robert W Buchanan
The potential of nicotinic enhancement of cognitive remediation training in schizophrenia.
Neuropharmacology 2013;64():185-90.
2012: Gregory Strauss; Robert P McMahon; Robert W Buchanan; William T Carpenter; Lauren T Catalano; Adam J Culbreth; Bernard A IV Fischer; James M Gold; William R Keller; Brian Kirkpatrick
Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale.
Schizophrenia research 2012;142(1-3):88-92.
2012: Gregory Strauss; Robert P McMahon; Robert W Buchanan; William T Carpenter; Lauren T Catalano; Adam J Culbreth; Bernard A IV Fischer; James M Gold; L Elliot Hong; William R Keller; Brian Kirkpatrick
Factor structure of the Brief Negative Symptom Scale.
Schizophrenia research 2012;142(1-3):96-8.
2012: Bernard A IV Fischer; Alan Francis; William R Keller; Brian Kirkpatrick; Robert P McMahon; Walter A Meyer; Godfrey D Pearlson; Celso Arango; William T Carpenter; Robert W Buchanan
Cortical structural abnormalities in deficit versus nondeficit schizophrenia.
Schizophrenia research 2012;136(1-3):51-4.
2012: Daniel C Javitt; Richard S E Keefe; Robert Kern; David Kimhy; Jeffrey Lieberman; Joseph P McEvoy; Robert P McMahon; Karen S Nolan; James Robinson; Larry J Seidman; M Patricia Ball; Deanna S Barch; Robert W Buchanan; John G Csernansky; Donald C Goff; James M Gold; Michael F Green; Fred Jarskog; Stephen R Marder
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.
Schizophrenia research 2012;136(1-3):25-31.
2012: Gregory Strauss; Daniel N Allen; Robert W Buchanan; Brian Kirkpatrick; Pinar Miski; William T Carpenter
Differential patterns of premorbid social and academic deterioration in deficit and nondeficit schizophrenia.
Schizophrenia research 2012;135(1-3):134-8.
2012: Robert W Buchanan; Armin Szegedi; Nina Schooler; Wil den Hollander; Larry Alphs; John Panagides; Alex Kouassi; Phillip Phiri; Jun Zhao; Xianwei Ha; Pilar Cazorla
Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia.
Journal of clinical psychopharmacology 2012;32(1):36-45.
2012: Douglas L Boggs; Robert R Conley; James M Gold; David A Gorelick; Marilyn A Huestis; Deanna L Kelly; Jared Linthicum; Fang Liu; Robert P McMahon; James A Waltz; Robert W Buchanan
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.
Schizophrenia research 2012;134(2-3):207-10.
2012: Elaine Weiner; M Patricia Ball; Alison S Buchholz; A Eden Evins; James M Gold; Robert P McMahon; Robert W Buchanan
Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis.
The Journal of clinical psychiatry 2012;73(1):95-102.
2011: Deanna L Kelly; Maju Koola; Robert P McMahon; Charles M Richardson; Gopal Vyas; Robert W Buchanan; Heidi Wehring
Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms.
Schizophrenia research 2011;133(1-3):257-8.
2011: L Elliot Hong; Robert P McMahon; Carol Myers; Jill RachBeisel; Ann Summerfelt; Gunvant K Thaker; Ikwunga Wonodi; Jeff Yang; Robert W Buchanan; Rebecca L Fuller; STEPHEN HEISHMAN; Adrienne Nye
Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.
Archives of general psychiatry 2011;68(12):1195-206.
2011: Robert W Buchanan; Michael F Green; Richard S E Keefe; Thomas Laughren; Daniel Umbricht; Stephen R Marder
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?
Schizophrenia bulletin 2011;37(6):1209-17.
2011: Stephen R Marder; Bita Moghaddam; Eric J Nestler; Bryan Roth; Akira Saw; Edward M Scolnick; Patrick F Sullivan; Daniel R Welnberger; Akira Sawa; Schahram Akbarian; John A Allen; Robert W Buchanan; Brian Campbell; Marc G Caron; P Jeffrey Conn; Susan R George; Mark A Geyer; Jay A Gingrich; Alessandro Guidotti; Stephen J Haggarty; Maria Karayiorgou; John H Krystal; Amanda J Law; Jeffrey A Lieberman; Michelle Solis
Advancing drug discovery for schizophrenia.
Annals of the New York Academy of Sciences 2011;1236():30-43.
2011: Cameron S Carter; Jonathan D Cohen; Mark Geyer; Randy Gollub; Michael F Green; Judith Jaeger; John H Krystal; Holly Moore; Keith Nuechterlein; Trevor Robbins; Steven Silverstein; Edward E Smith; Milton Strauss; Deanna M Barch; James Breiling; Robert W Buchanan; Edward Bullmore; Pamela Butler; Til Wykes
Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders.
Biological psychiatry 2011;70(1):7-12.
2011: Elaine Weiner; Alison Buchholz; Agnes Coffay; Fang Liu; Robert P McMahon; Robert W Buchanan; Deanna L Kelly
Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study.
Schizophrenia research 2011;129(1):94-5.
2011: M Patricia Ball; Kimberly R Warren; Stephanie Feldman; Robert P McMahon; Deanna L Kelly; Robert W Buchanan
Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.
Clinical schizophrenia & related psychoses 2011;5(1):17-25.
2011: Robert W Buchanan; Richard S E Keefe; Jeffrey A Lieberman; Deanna M Barch; John G Csernansky; Donald C Goff; James M Gold; Michael F Green; L Fredrik Jarskog; Daniel C Javitt; David Kimhy; Michael S Kraus; Joseph P McEvoy; Raquelle I Mesholam-Gately; Larry J Seidman; M Patricia Ball; Robert P McMahon; Robert S Kern; James Robinson; Stephen R Marder
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.
Biological psychiatry 2011;69(5):442-9.
2011: Monica C Mann-Wrobel; Melanie E Bennett; Elaine Weiner; Robert W Buchanan; M Patricia Ball
Smoking history and motivation to quit in smokers with schizophrenia in a smoking cessation program.
Schizophrenia research 2011;126(1-3):277-83.
2011: Deanna L Kelly; David A Gorelick; Robert R Conley; Douglas L Boggs; Jared Linthicum; Fang Liu; Stephanie Feldman; M Patricia Ball; Heidi Wehring; Robert P McMahon; Marilyn A Huestis; STEPHEN HEISHMAN; Kimberly R Warren; Robert W Buchanan
Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.
Journal of clinical psychopharmacology 2011;31(1):86-91.
2011: Robert W Buchanan; Robert Schwarcz
α7 Nicotinic receptor agonists as cognitive treatments: is less (or less often) more?
Biological psychiatry 2011;69(1):5-6.
2010: Elaine Weiner; Robert R Conley; M Patricia Ball; Stephanie Feldman; James M Gold; Deanna L Kelly; Ikwunga Wonodi; Robert P McMahon; Robert W Buchanan
Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2010;35(11):2274-83.
2010: L Elliot Hong; Ann Summerfelt; Robert W Buchanan; Patricio O'Donnell; Gunvant K Thaker; Martin A Weiler; Adrienne C Lahti
Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2010;35(3):632-40.
2010: Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M. Noel; Douglas L Boggs; Bernard A IV Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.
Schizophrenia bulletin 2010;36(1):71-93.
2010: Julie Kreyenbuhl; Robert W Buchanan; Faith B Dickerson; Lisa Dixon
The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.
Schizophrenia bulletin 2010;36(1):94-103.
2009: Christine E Marx; Richard S E Keefe; Robert W Buchanan; Robert M Hamer; Jason D Kilts; Daniel W Bradford; Jennifer L Strauss; Jennifer C Naylor; Victoria M Payne; Jeffrey A Lieberman; Adam J Savitz; Linda A Leimone; Lawrence Dunn; Patrizia Porcu; A Leslie Morrow; Lawrence J Shampine
Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2009;34(8):1885-903.
2009: Deanna L Kelly; Elaine Weiner; M Patricia Ball; Robert P McMahon; William T Carpenter; Robert W Buchanan
Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study.
Journal of psychopharmacology (Oxford, England) 2009;23(4):436-41.
2009: Laura M Rowland; Elena A Spieker; Alan Francis; Peter B Barker; William T Carpenter; Robert W Buchanan
White matter alterations in deficit schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2009;34(6):1514-22.
2009: Deanna L Kelly; Robert W Buchanan; Douglas L Boggs; Robert P McMahon; Dwight Dickinson; Matthew Nelson; James M Gold; M Patricia Ball; Stephanie Feldman; Fang Liu; Robert R Conley
A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia.
The Journal of clinical psychiatry 2009;70(4):518-25.
2009: Robert R Conley; Douglas L Boggs; Deanna L Kelly; Robert P McMahon; Dwight Dickinson; Stephanie Feldman; M Patricia Ball; Robert W Buchanan
The effects of galantamine on psychopathology in chronic stable schizophrenia.
Clinical neuropharmacology 2009;32(2):69-74.
2009: Deanna M Barch; Cameron S Carter; Amy Arnsten; Robert W Buchanan; Jonathan D Cohen; Mark A Geyer; Michael F Green; John H Krystal; Keith Nuechterlein; Trevor W Robbins; Steven Silverstein; Edward E Smith; Milton Strauss; Til Wykes; Robert Heinssen
Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting.
Schizophrenia bulletin 2009;35(1):109-14.
2008: Kristen J Prentice; James M Gold; Robert W Buchanan
The Wisconsin Card Sorting impairment in schizophrenia is evident in the first four trials.
Schizophrenia research 2008;106(1):81-7.
2008: L Elliot Hong; Ann Summerfelt; Braxton D Mitchell; Robert P McMahon; Ikwunga Wonodi; Robert W Buchanan; Gunvant K Thaker
Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate.
Archives of general psychiatry 2008;65(9):1008-16.
2008: Deanna L Kelly; Robert P McMahon; Elaine Weiner; Douglas L Boggs; Dwight Dickinson; Robert R Conley; Robert W Buchanan
Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.
Schizophrenia research 2008;103(1-3):161-8.
2008: Robert Freedman; Ann Olincy; Robert W Buchanan; Josette G Harris; James M Gold; Lynn Johnson; Diana Allensworth; Alejandrina Guzman-Bonilla; Bettye Clement; M Patricia Ball; Jay Kutnick; Vicki Pender; Laura F Martin; Karen E Stevens; Brandie D Wagner; Gary O Zerbe; Ferenc Soti; William R Kem
Initial phase 2 trial of a nicotinic agonist in schizophrenia.
The American journal of psychiatry 2008;165(8):1040-7.
2008: Cameron S Carter; Deanna M Barch; Robert W Buchanan; Ed Bullmore; John H Krystal; Jonathan Cohen; Mark A Geyer; Michael Green; Keith H Nuechterlein; Trevor W Robbins; Steven Silverstein; Edward E Smith; Milton Strauss; Til Wykes; Robert Heinssen
Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative.
Biological psychiatry 2008;64(1):4-10.
2008: William T Carpenter; Robert W Buchanan
Lessons to take home from CATIE.
Psychiatric services (Washington, D.C.) 2008;59(5):523-5.
2008: Richard S E Keefe; Anil Malhotra; Herbert Y Meltzer; John M Kane; Robert W Buchanan; Anita Murthy; Mindy Sovel; Chunming Li; Robert Goldman
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2008;33(6):1217-28.
2008: Shashwath A Meda; Nicole R Giuliani; Vince D Calhoun; Kanchana Jagannathan; David J Schretlen; Ann E Pulver; Nicola G Cascella; Matcheri S Keshavan; Wendy Kates; Robert W Buchanan; Tonmoy Sharma; Godfrey D Pearlson
A large scale (N=400) investigation of gray matter differences in schizophrenia using optimized voxel-based morphometry.
Schizophrenia research 2008;101(1-3):95-105.
2008: L Elliot Hong; Robert W Buchanan; Gunvant K Thaker; Paul D Shepard; Ann Summerfelt
Beta (~16 Hz) frequency neural oscillations mediate auditory sensory gating in humans.
Psychophysiology 2008;45(2):197-204.
2008: Celso Arango; Robert P McMahon; David M Lefkowitz; Godfrey D Pearlson; Brian Kirkpatrick; Robert W Buchanan
Patterns of cranial, brain and sulcal CSF volumes in male and female deficit and nondeficit patients with schizophrenia.
Psychiatry research 2008;162(2):91-100.
2008: Robert W Buchanan; Robert R Conley; Dwight Dickinson; M Patricia Ball; Stephanie Feldman; James M Gold; Robert P McMahon
Galantamine for the treatment of cognitive impairments in people with schizophrenia.
The American journal of psychiatry 2008;165(1):82-9.
2007: Troy A Moore; Robert W Buchanan; Peter F Buckley; John A Chiles; Robert R Conley; M Lynn Crismon; Susan M Essock; Molly Finnerty; Stephen R Marder; Joseph P McEvoy; Delbert Robinson; Nina R Schooler; Steven P Shon; Thomas Stroup; Del D Miller; Alexander Miller
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.
The Journal of clinical psychiatry 2007;68(11):1751-62.
2007: Robert W Buchanan; Daniel C Javitt; Stephen R Marder; Nina R Schooler; James M Gold; Robert P McMahon; Uriel Heresco-Levy; William T Carpenter
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
The American journal of psychiatry 2007;164(10):1593-602.
2007: Robert W Buchanan; Robert Freedman; Daniel C Javitt; Anissa Abi-Dargham; Jeffrey A Lieberman
Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.
Schizophrenia bulletin 2007;33(5):1120-30.
2007: Alex S Cohen; Alice M Saperstein; James M Gold; Brian Kirkpatrick; William T Carpenter; Robert W Buchanan
Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date.
Schizophrenia bulletin 2007;33(5):1201-12.
2007: Robert W Buchanan
Persistent negative symptoms in schizophrenia: an overview.
Schizophrenia bulletin 2007;33(4):1013-22.
2007: L Elliot Hong; Ann Summerfelt; Ikwunga Wonodi; Helene Adami; Robert W Buchanan; Gunvant K Thaker
Independent domains of inhibitory gating in schizophrenia and the effect of stimulus interval.
The American journal of psychiatry 2007;164(1):61-5.
2007: Adegboyega Sapara; Michael Cooke; Dominic Fannon; Alan Francis; Robert W Buchanan; Anantha P P Anilkumar; Ian Barkataki; Ingrid Aasen; Elizabeth Kuipers; Veena Kumari
Prefrontal cortex and insight in schizophrenia: a volumetric MRI study.
Schizophrenia research 2007;89(1-3):22-34.
2006: Robert W Buchanan
Important steps in the development of cognitive-enhancing drugs in schizophrenia.
The American journal of psychiatry 2006;163(11):1867-9.
2006: Louis S Matza; Robert W Buchanan; Scot Purdon; Jessica Brewster-Jordan; Yang Zhao; Dennis A Revicki
Measuring changes in functional status among patients with schizophrenia: the link with cognitive impairment.
Schizophrenia bulletin 2006;32(4):666-78.
2006: David Potter; Ann Summerfelt; James M Gold; Robert W Buchanan
Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia.
Schizophrenia bulletin 2006;32(4):692-700.
2006: Hugh M D Gurling; Hugo Critchley; Susmita R Datta; Andrew McQuillin; Ekaterina Blaveri; Srinivasa Thirumalai; Jonathan Pimm; Robert Krasucki; Gursharan Kalsi; Digby Quested; Jacob Lawrence; Nicholas Bass; Khalid Choudhury; Vinay Puri; Owen O'Daly; David Curtis; Douglas Blackwood; Walter Muir; Anil Malhotra; Robert W Buchanan; Catriona D Good; Richard S J Frackowiak; Raymond J Dolan
Genetic association and brain morphology studies and the chromosome 8p22 pericentriolar material 1 (PCM1) gene in susceptibility to schizophrenia.
Archives of general psychiatry 2006;63(8):844-54.
2006: Ikwunga Wonodi; Braxton D Mitchell; O Colin Stine; L Elliot Hong; Amie Elliott; Brian Kirkpatrick; William T Carpenter; Gunvant K Thaker; Robert W Buchanan
Lack of association between COMT gene and deficit/nondeficit schizophrenia.
Behavioral and brain functions : BBF 2006;2():42.
2006: Matthew W Nelson; Robert W Buchanan
Galantamine-induced QTc prolongation.
The Journal of clinical psychiatry 2006;67(1):166-7.
2005: Christopher M Wilk; James M Gold; Robert P McMahon; Katherine Humber; Virginia N Iannone; Robert W Buchanan
No, it is not possible to be schizophrenic yet neuropsychologically normal.
Neuropsychology 2005;19(6):778-86.
2005: Ikwunga Wonodi; L Elliot Hong; Matthew T Avila; Robert W Buchanan; William T Carpenter; O Colin Stine; Braxton D Mitchell; Gunvant K Thaker
Association between polymorphism of the SNAP29 gene promoter region and schizophrenia.
Schizophrenia research 2005;78(2-3):339-41.
2005: Igor Bombin; Celso Arango; Robert W Buchanan
Significance and meaning of neurological signs in schizophrenia: two decades later.
Schizophrenia bulletin 2005;31(4):962-77.
2005: L Elliot Hong; Ikwunga Wonodi; Matthew T Avila; Robert W Buchanan; Robert P McMahon; Braxton D Mitchell; O Colin Stine; William T Carpenter; Gunvant K Thaker
Dihydropyrimidinase-related protein 2 (DRP-2) gene and association to deficit and nondeficit schizophrenia.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2005;136B(1):8-11.
2005: Nicole R Giuliani; Vince D Calhoun; Godfrey D Pearlson; Alan Francis; Robert W Buchanan
Voxel-based morphometry versus region of interest: a comparison of two methods for analyzing gray matter differences in schizophrenia.
Schizophrenia research 2005;74(2-3):135-47.
2005: Robert W Buchanan; Miriam Davis; Donald Goff; Michael F Green; Richard S E Keefe; Andrew C Leon; Keith H Nuechterlein; Thomas Laughren; Robert Levin; Ellen Stover; Wayne S Fenton; Stephen R Marder
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.
Schizophrenia bulletin 2005;31(1):5-19.
2005: Robert W Buchanan; M Patricia Ball; Elaine Weiner; Brian Kirkpatrick; James M Gold; Robert P McMahon; William T Carpenter
Olanzapine treatment of residual positive and negative symptoms.
The American journal of psychiatry 2005;162(1):124-9.
2004: Robert W Buchanan; Godfrey D Pearlson
Prefrontal cortex, structural analysis: segmenting the prefrontal cortex.
The American journal of psychiatry 2004;161(11):1978.
2004: Erick Messias; Brian Kirkpatrick; Evelyn J Bromet; David E Ross; Robert W Buchanan; William T Carpenter; Cenk Tek; Kenneth S Kendler; Dermot Walsh; Sonia Dollfus
Summer birth and deficit schizophrenia: a pooled analysis from 6 countries.
Archives of general psychiatry 2004;61(10):985-9.
2004: L Elliot Hong; Ann Summerfelt; Robert P McMahon; Helene Adami; Grace Francis; Amie Elliott; Robert W Buchanan; Gunvant K Thaker
Evoked gamma band synchronization and the liability for schizophrenia.
Schizophrenia research 2004;70(2-3):293-302.
2004: Christopher M Wilk; James M Gold; Kathy Humber; Faith B Dickerson; Wayne S Fenton; Robert W Buchanan
Brief cognitive assessment in schizophrenia: normative data for the Repeatable Battery for the Assessment of Neuropsychological Status.
Schizophrenia research 2004;70(2-3):175-86.
2004: Stephen R Marder; Susan M Essock; Alexander Miller; Robert W Buchanan; Daniel E Casey; John M Davis; John M Kane; Jeffrey A Lieberman; Nina R Schooler; Nancy H Covell; Scott Stroup; Ellen M Weissman; Donna A Wirshing; Catherine S Hall; Leonard Pogach; Xavier Pi-Sunyer; J Thomas Bigger; Alan Friedman; David Kleinberg; Steven J Yevich; Bonnie Davis; Steven P Shon
Physical health monitoring of patients with schizophrenia.
The American journal of psychiatry 2004;161(8):1334-49.
2004: James M Gold; Michael S Poet; Christopher M Wilk; Robert W Buchanan
The family pictures test as a measure of impaired feature binding in schizophrenia.
Journal of clinical and experimental neuropsychology 2004;26(4):511-20.
2004: Alexander Miller; Catherine S Hall; Robert W Buchanan; Peter F Buckley; John A Chiles; Robert R Conley; M Lynn Crismon; Larry Ereshefsky; Susan M Essock; Molly Finnerty; Stephen R Marder; Del D Miller; Joseph P McEvoy; A John Rush; Sy A Saeed; Nina R Schooler; Steven P Shon; Scott Stroup; Bernardo Tarin-Godoy
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.
The Journal of clinical psychiatry 2004;65(4):500-8.
2004: Celso Arango; Robert W Buchanan; Brian Kirkpatrick; William T Carpenter
The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms.
European psychiatry : the journal of the Association of European Psychiatrists 2004;19(1):21-6.
2004: Robert W Buchanan; Alan Francis; Celso Arango; Karl Miller; David M Lefkowitz; Robert P McMahon; Patrick Barta; Godfrey D Pearlson
Morphometric assessment of the heteromodal association cortex in schizophrenia.
The American journal of psychiatry 2004;161(2):322-31.
2004: L Elliot Hong; Ann Summerfelt; Robert P McMahon; Gunvant K Thaker; Robert W Buchanan
Gamma/beta oscillation and sensory gating deficit in schizophrenia.
Neuroreport 2004;15(1):155-9.
2004: Anthony Lehman; Julie Kreyenbuhl; Robert W Buchanan; Faith B Dickerson; Lisa Dixon; Richard W Goldberg; Lisa D Green-Paden; Wendy N Tenhula; Daniela Boerescu; Cenk Tek; Neil Sandson; Donald M Steinwachs
The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003.
Schizophrenia bulletin 2004;30(2):193-217.
2003: Anthony Lehman; Robert W Buchanan; Faith B Dickerson; Lisa Dixon; Richard W Goldberg; Lisa D Green-Paden; Julie Kreyenbuhl
Evidence-based treatment for schizophrenia.
The Psychiatric clinics of North America 2003;26(4):939-54.
2003: Celso Arango; Ann Summerfelt; Robert W Buchanan
Olanzapine effects on auditory sensory gating in schizophrenia.
The American journal of psychiatry 2003;160(11):2066-8.
2003: Celso Arango; Alan Breier; Robert P McMahon; William T Carpenter; Robert W Buchanan
The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes.
The American journal of psychiatry 2003;160(8):1421-7.
2003: Ikwunga Wonodi; O Colin Stine; Braxton D Mitchell; Robert W Buchanan; Gunvant K Thaker
Association between Val108/158 Met polymorphism of the COMT gene and schizophrenia.
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics 2003;120B(1):47-50.
2003: James M Gold; Christopher M Wilk; Robert P McMahon; Robert W Buchanan; Steven J Luck
Working memory for visual features and conjunctions in schizophrenia.
Journal of abnormal psychology 2003;112(1):61-71.
2003: Julie Kreyenbuhl; Julie M. Zito; Robert W Buchanan; Karen Soeken; Anthony Lehman
Racial disparity in the pharmacological management of schizophrenia.
Schizophrenia bulletin 2003;29(2):183-93.
2003: Scott P Baymiller; M Patricia Ball; Robert P McMahon; Robert W Buchanan
Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment.
Schizophrenia research 2003;59(1):49-57.
2003: Robert W Buchanan; Ann Summerfelt; Cenk Tek; James M Gold
An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia.
Schizophrenia research 2003;59(1):29-33.
2002: Carol E Koro; Donald O. Fedder; Gilbert J L'Italien; Sheila Weiss Smith; Laurence S Magder; Julie Kreyenbuhl; Dennis Revicki; Robert W Buchanan
An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.
Archives of general psychiatry 2002;59(11):1021-6.
2002: Carol E Koro; Donald O. Fedder; Gilbert J L'Italien; Sheila Weiss Smith; Laurence S Magder; Julie Kreyenbuhl; Dennis A Revicki; Robert W Buchanan
Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.
BMJ (Clinical research ed.) 2002;325(7358):243.
2002: Scott P Baymiller; M Patricia Ball; Robert P McMahon; Robert W Buchanan
Weight and blood pressure change during clozapine treatment.
Clinical neuropharmacology 2002;25(4):202-6.
2002: Robert W Buchanan; Julie Kreyenbuhl; Julie M. Zito; Anthony Lehman
Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia.
The American journal of psychiatry 2002;159(6):1035-43.
2002: Christopher M Wilk; James M Gold; John J Bartko; Faith B Dickerson; Wayne S Fenton; Michael B Knable; Christopher Randolph; Robert W Buchanan
Test-retest stability of the Repeatable Battery for the Assessment of Neuropsychological Status in schizophrenia.
The American journal of psychiatry 2002;159(5):838-44.
2002: Cenk Tek; James M Gold; Teresa Blaxton; Christopher M Wilk; Robert P McMahon; Robert W Buchanan
Visual perceptual and working memory impairments in schizophrenia.
Archives of general psychiatry 2002;59(2):146-53.
2002: Susan DosReis; Julie M. Zito; Robert W Buchanan; Anthony Lehman
Antipsychotic dosing and concurrent psychotropic treatments for Medicaid-insured individuals with schizophrenia.
Schizophrenia bulletin 2002;28(4):607-17.
2002: William T Carpenter; Robert W Buchanan
Commentary on the Soteria project: misguided therapeutics.
Schizophrenia bulletin 2002;28(4):577-81; discussion 583-8.
2002: Robert W Buchanan; Julie Kreyenbuhl; Julie M. Zito; Anthony Lehman
The schizophrenia PORT pharmacological treatment recommendations: conformance and implications for symptoms and functional outcome.
Schizophrenia bulletin 2002;28(1):63-73.
2002: Stephen R Marder; Susan M Essock; Alexander Miller; Robert W Buchanan; John M Davis; John M Kane; Jeffrey Lieberman; Nina R Schooler
The Mount Sinai conference on the pharmacotherapy of schizophrenia.
Schizophrenia bulletin 2002;28(1):5-16.
2001: M Patricia Ball; V B Coons; Robert W Buchanan
A program for treating olanzapine-related weight gain.
Psychiatric services (Washington, D.C.) 2001;52(7):967-9.
2001: Cenk Tek; Brian Kirkpatrick; Robert W Buchanan
A five-year followup study of deficit and nondeficit schizophrenia.
Schizophrenia research 2001;49(3):253-60.
2001: Elaine Weiner; M Patricia Ball; Ann Summerfelt; James M Gold; Robert W Buchanan
Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia.
The American journal of psychiatry 2001;158(4):635-7.
2001: Brian Kirkpatrick; Robert W Buchanan; David E Ross; William T Carpenter
A separate disease within the syndrome of schizophrenia.
Archives of general psychiatry 2001;58(2):165-71.
2000: C R Blyler; James M Gold; Virginia N Iannone; Robert W Buchanan
Short form of the WAIS-III for use with patients with schizophrenia.
Schizophrenia research 2000;46(2-3):209-15.
2000: Alan Breier; Robert W Buchanan; D Irish; William T Carpenter
Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. 1993.
Psychiatric services (Washington, D.C.) 2000;51(10):1249-53.
2000: William T Carpenter; Alan Breier; Robert W Buchanan; Brian Kirkpatrick; Paul D Shepard; Elaine Weiner
Mazindol treatment of negative symptoms.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2000;23(4):365-74.
2000: James M Gold; J A Bish; Virginia N Iannone; M P Hobart; CA Queern; Robert W Buchanan
Effects of contextual processing on visual conditional associative learning in schizophrenia.
Biological psychiatry 2000;48(5):406-14.
2000: Celso Arango; Brian Kirkpatrick; Robert W Buchanan
Neurological signs and the heterogeneity of schizophrenia.
The American journal of psychiatry 2000;157(4):560-5.
2000: Brian Kirkpatrick; A Kopelowicz; Robert W Buchanan; William T Carpenter
Assessing the efficacy of treatments for the deficit syndrome of schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2000;22(3):303-10.
2000: Peter F Buckley; Robert W Buchanan; Carol A Tamminga; S C Schulz
Schizophrenia research: a progress report, summarizing proceedings of the 1999 International Congress on Schizophrenia Research.
Schizophrenia bulletin 2000;26(2):411-9.
2000: Celso Arango; Brian Kirkpatrick; Robert W Buchanan
Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms.
The Journal of nervous and mental disease 2000;188(1):50-3.
1999: James M Gold; CA Queern; Virginia N Iannone; Robert W Buchanan
Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity.
The American journal of psychiatry 1999;156(12):1944-50.
1999: Gunvant K Thaker; David E Ross; Robert W Buchanan; Helene Adami; Deborah R Medoff
Smooth pursuit eye movements to extra-retinal motion signals: deficits in patients with schizophrenia.
Psychiatry research 1999;88(3):209-19.
1999: William T Carpenter; Brian Kirkpatrick; Robert W Buchanan
Schizophrenia: syndromes and diseases.
Journal of psychiatric research 1999;33(6):473-5.
1999: Celso Arango; John J Bartko; James M Gold; Robert W Buchanan
Prediction of neuropsychological performance by neurological signs in schizophrenia.
The American journal of psychiatry 1999;156(9):1349-57.
1999: William T Carpenter; Celso Arango; Robert W Buchanan; Brian Kirkpatrick
Deficit psychopathology and a paradigm shift in schizophrenia research.
Biological psychiatry 1999;46(3):352-60.
1999: Xavier F Amador; Brian Kirkpatrick; Robert W Buchanan; William T Carpenter; L Marcinko; Scott Yale
Stability of the diagnosis of deficit syndrome in schizophrenia.
The American journal of psychiatry 1999;156(4):637-9.
1999: N L Bryant; Robert W Buchanan; K Vladar; Alan Breier; MI Rothman
Gender differences in temporal lobe structures of patients with schizophrenia: a volumetric MRI study.
The American journal of psychiatry 1999;156(4):603-9.
1999: William T Carpenter; Robert W Buchanan; Brian Kirkpatrick; H D Lann; Alan Breier; Ann Summerfelt
Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks.
The American journal of psychiatry 1999;156(3):412-8.
1999: William T Carpenter; Robert W Buchanan; Brian Kirkpatrick; Alan Breier
Diazepam treatment of early signs of exacerbation in schizophrenia.
The American journal of psychiatry 1999;156(2):299-303.
1999: Alan S Bellack; James M Gold; Robert W Buchanan
Cognitive rehabilitation for schizophrenia: problems, prospects, and strategies.
Schizophrenia bulletin 1999;25(2):257-74.
1998: David E Ross; Robert W Buchanan; Deborah R Medoff; Adrienne C Lahti; Gunvant K Thaker
Association between eye tracking disorder in schizophrenia and poor sensory integration.
The American journal of psychiatry 1998;155(10):1352-7.
1998: Brian Kirkpatrick; R Ram; X F Amador; Robert W Buchanan; T McGlashan; M Tohen; E Bromet
Summer birth and the deficit syndrome of schizophrenia.
The American journal of psychiatry 1998;155(9):1221-6.
1998: Robert W Buchanan; K Vladar; Patrick Barta; Godfrey D Pearlson
Structural evaluation of the prefrontal cortex in schizophrenia.
The American journal of psychiatry 1998;155(8):1049-55.
1998: Robert W Buchanan; Alan Breier; Brian Kirkpatrick; M Patricia Ball; William T Carpenter
Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome.
The American journal of psychiatry 1998;155(6):751-60.
1998: David E Ross; Robert W Buchanan; Adrienne C Lahti; Deborah R Medoff; John J Bartko; Ann Compton; Gunvant K Thaker
The relationship between smooth pursuit eye movements and tardive dyskinesia in schizophrenia.
Schizophrenia research 1998;31(2-3):141-50.
1998: Celso Arango; Brian Kirkpatrick; Robert W Buchanan; William T Carpenter
[The deficit syndrome: a domain of schizophrenia].
Actas luso-españolas de neurología, psiquiatría y ciencias afines 1998;26(3):180-6.
1998: Carol A Tamminga; Robert W Buchanan; James M Gold
The role of negative symptoms and cognitive dysfunction in schizophrenia outcome.
International clinical psychopharmacology 1998;13 Suppl 3():S21-6.
1998: David E Ross; Gunvant K Thaker; Robert W Buchanan; Adrienne C Lahti; Robert R Conley; Deborah R Medoff
Specific measures account for most of the variance in qualitative ratings of smooth pursuit eye movements in schizophrenia.
Archives of general psychiatry 1998;55(2):184-6.
1998: Robert W Buchanan; Peter F Buckley; Carol A Tamminga; S C Schulz
Schizophrenia research: a biennium of progress. Proceedings from the Sixth International Congress on Schizophrenia Research. Colorado Springs, CO, April 12-16, 1997.
Schizophrenia bulletin 1998;24(4):501-18.
1998: Anil Malhotra; David Goldman; Robert W Buchanan; W Rooney; A Clifton; Mary Kosmidis; Alan Breier; DAVID PICKAR
The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response.
Molecular psychiatry 1998;3(1):72-5.
1997: David E Ross; Gunvant K Thaker; Robert W Buchanan; Brian Kirkpatrick; Adrienne C Lahti; Deborah R Medoff; John J Bartko; J Goodman; Allen Tien
Eye tracking disorder in schizophrenia is characterized by specific ocular motor defects and is associated with the deficit syndrome.
Biological psychiatry 1997;42(9):781-96.
1997: Brian Kirkpatrick; D Litman; J W Kim; K Vladar; Alan Breier; Robert W Buchanan
Failure of fusion of the septum pellucidum and the heterogeneity of schizophrenia.
The Journal of nervous and mental disease 1997;185(10):639-41.
1997: Juan R Bustillo; Gunvant K Thaker; Robert W Buchanan; M Moran; Brian Kirkpatrick; William T Carpenter
Visual information-processing impairments in deficit and nondeficit schizophrenia.
The American journal of psychiatry 1997;154(5):647-54.
1997: Robert W Buchanan; M E Strauss; Alan Breier; Brian Kirkpatrick; William T Carpenter
Attentional impairments in deficit and nondeficit forms of schizophrenia.
The American journal of psychiatry 1997;154(3):363-70.
1997: Royce Waltrip II; Robert W Buchanan; William T Carpenter; Brian Kirkpatrick; Ann Summerfelt; Alan Breier; Steven A Rubin; Kathryn M Carbone
Borna disease virus antibodies and the deficit syndrome of schizophrenia.
Schizophrenia research 1997;23(3):253-7.
1997: Robert R Conley; Robert W Buchanan
Evaluation of treatment-resistant schizophrenia.
Schizophrenia bulletin 1997;23(4):663-74.
1997: Robert W Buchanan; William T Carpenter
The neuroanatomies of schizophrenia.
Schizophrenia bulletin 1997;23(3):367-72.
1996: Robert W Buchanan; Brian Kirkpatrick; N Bryant; M Patricia Ball; Alan Breier
Fluoxetine augmentation of clozapine treatment in patients with schizophrenia.
The American journal of psychiatry 1996;153(12):1625-7.
1996: William T Carpenter; Robert R Conley; Robert W Buchanan; Alan Breier; Carol A Tamminga
Clozapine conflict.
The American journal of psychiatry 1996;153(11):1505-7.
1996: Anil Malhotra; David Goldman; N Ozaki; W Rooney; A Clifton; Robert W Buchanan; Alan Breier; DAVID PICKAR
Clozapine response and the 5HT2C Cys23Ser polymorphism.
Neuroreport 1996;7(13):2100-2.
1996: David E Ross; Gunvant K Thaker; Robert W Buchanan; Adrienne C Lahti; Deborah R Medoff; John J Bartko; M Moran; J Hartley
Association of abnormal smooth pursuit eye movements with the deficit syndrome in schizophrenic patients.
The American journal of psychiatry 1996;153(9):1158-65.
1996: Anil Malhotra; David Goldman; N Ozaki; Alan Breier; Robert W Buchanan; DAVID PICKAR
Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine.
The American journal of psychiatry 1996;153(8):1092-4.
1996: Anil Malhotra; David Goldman; Robert W Buchanan; Alan Breier; DAVID PICKAR
5HT 2a receptor T102C polymorphism and schizophrenia.
Lancet 1996;347(9018):1830-1.
1996: J R Bustillo; Robert W Buchanan; D Irish; Alan Breier
Differential effect of clozapine on weight: a controlled study.
The American journal of psychiatry 1996;153(6):817-9.
1996: Robert W Buchanan; James M Gold
Negative symptoms: diagnosis, treatment and prognosis.
International clinical psychopharmacology 1996;11 Suppl 2():3-11.
1996: Brian Kirkpatrick; Xavier F Amador; Scott Yale; J R Bustillo; Robert W Buchanan; Mauricio Tohen
The deficit syndrome in the DSM-IV Field Trial. Part II. Depressive episodes and persecutory beliefs.
Schizophrenia research 1996;20(1-2):79-90.
1996: Peter F Buckley; Robert W Buchanan; S Charles Schulz; Carol A Tamminga
Catching up on schizophrenia. The Fifth International Congress on Schizophrenia Research, Warm Springs, Va, April 8-12, 1995.
Archives of general psychiatry 1996;53(5):456-62.
1996: Gunvant K Thaker; David E Ross; Robert W Buchanan; M J Moran; Adrienne C Lahti; C Kim; Deborah R Medoff
Does pursuit abnormality in schizophrenia represent a deficit in the predictive mechanism?
Psychiatry research 1996;59(3):221-37.
1995: J R Bustillo; Robert W Buchanan
Neuroleptic-induced emesis: a new indication for clozapine?
Biological psychiatry 1995;38(3):194-5.
1995: J R Bustillo; Brian Kirkpatrick; Robert W Buchanan
Neuroleptic treatment and negative symptoms in deficit and nondeficit schizophrenia.
Biological psychiatry 1995;38(1):64-7.
1995: William T Carpenter; Robert R Conley; Robert W Buchanan; Alan Breier; Carol A Tamminga
Patient response and resource management: another view of clozapine treatment of schizophrenia.
The American journal of psychiatry 1995;152(6):827-32.
1995: Royce Waltrip II; Robert W Buchanan; Ann Summerfelt; Alan Breier; William T Carpenter; N L Bryant; Steven A Rubin; Kathryn M Carbone
Borna disease virus and schizophrenia.
Psychiatry research 1995;56(1):33-44.
1995: Robert W Buchanan
Clozapine: efficacy and safety.
Schizophrenia bulletin 1995;21(4):579-91.
1995: J Bustillo; Robert W Buchanan; William T Carpenter
Prodromal symptoms vs. early warning signs and clinical action in schizophrenia.
Schizophrenia bulletin 1995;21(4):553-9.
1995: William T Carpenter; Robert W Buchanan; Brian Kirkpatrick
New diagnostic issues in schizophrenic disorders.
Clinical neuroscience (New York, N.Y.) 1995;3(2):57-63.
1994: Robert W Buchanan; C Holstein; Alan Breier
The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.
Biological psychiatry 1994;36(11):717-25.
1994: Robert W Buchanan; M E Strauss; Brian Kirkpatrick; C Holstein; Alan Breier; William T Carpenter
Neuropsychological impairments in deficit vs nondeficit forms of schizophrenia.
Archives of general psychiatry 1994;51(10):804-11.
1994: Brian Kirkpatrick; Robert W Buchanan; Alan Breier; William T Carpenter
Depressive symptoms and the deficit syndrome of schizophrenia.
The Journal of nervous and mental disease 1994;182(8):452-5.
1994: Robert W Buchanan; P Koeppl; Alan Breier
Stability of neurological signs with clozapine treatment.
Biological psychiatry 1994;36(3):198-200.
1994: A M Elkashef; Robert W Buchanan; FOUAD GELLAD; Robert C Munson; Alan Breier
Basal ganglia pathology in schizophrenia and tardive dyskinesia: an MRI quantitative study.
The American journal of psychiatry 1994;151(5):752-5.
1994: Robert W Buchanan; William T Carpenter
Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia.
The Journal of nervous and mental disease 1994;182(4):193-204.
1994: William T Carpenter; Robert W Buchanan
Schizophrenia.
The New England journal of medicine 1994;330(10):681-90.
1994: Alan Breier; Robert W Buchanan; Royce Waltrip II; S Listwak; C Holmes; David S Goldstein
The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1994;10(1):1-7.
1994: Alan Breier; Robert W Buchanan; Brian Kirkpatrick; O R Davis; D Irish; Ann Summerfelt; William T Carpenter
Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia.
The American journal of psychiatry 1994;151(1):20-6.
1993: Alan Breier; Robert W Buchanan; D Irish; William T Carpenter
Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns.
Hospital & community psychiatry 1993;44(12):1145-9.
1993: Alan Breier; Brian Kirkpatrick; Robert W Buchanan
Clozapine attenuates meta-chlorophenylpiperazine (mCPP)-induced plasma cortisol increases in schizophrenia.
Biological psychiatry 1993;34(7):492-4.
1993: William T Carpenter; Robert W Buchanan; Brian Kirkpatrick; Carol A Tamminga; F Wood
Strong inference, theory testing, and the neuroanatomy of schizophrenia.
Archives of general psychiatry 1993;50(10):825-31.
1993: Alan Breier; O R Davis; Robert W Buchanan; L A Moricle; Robert C Munson
Effects of metabolic perturbation on plasma homovanillic acid in schizophrenia. Relationship to prefrontal cortex volume.
Archives of general psychiatry 1993;50(7):541-50.
1993: M E Strauss; Robert W Buchanan; J Hale
Relations between attentional deficits and clinical symptoms in schizophrenic outpatients.
Psychiatry research 1993;47(3):205-13.
1993: Brian Kirkpatrick; Robert W Buchanan; Alan Breier; William T Carpenter
Case identification and stability of the deficit syndrome of schizophrenia.
Psychiatry research 1993;47(1):47-56.
1993: Robert W Buchanan; Alan Breier; Brian Kirkpatrick; A Elkashef; Robert C Munson; FOUAD GELLAD; William T Carpenter
Structural abnormalities in deficit and nondeficit schizophrenia.
The American journal of psychiatry 1993;150(1):59-65.
1992: Brian Kirkpatrick; William T Carpenter; K Maeda; Robert W Buchanan; Alan Breier; Carol A Tamminga
Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients.
Biological psychiatry 1992;32(11):1049-54.
1992: Alan Breier; Robert W Buchanan; A Elkashef; Robert C Munson; Brian Kirkpatrick; FOUAD GELLAD
Brain morphology and schizophrenia. A magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures.
Archives of general psychiatry 1992;49(12):921-6.
1992: Alan Breier; O Davis; Robert W Buchanan; S J Listwak; C Holmes; DAVID PICKAR; David S Goldstein
Effects of alprazolam on pituitary-adrenal and catecholaminergic responses to metabolic stress in humans.
Biological psychiatry 1992;32(10):880-90.
1992: Carol A Tamminga; Gunvant K Thaker; Robert W Buchanan; Brian Kirkpatrick; L D Alphs; Thomas N Chase; William T Carpenter
Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome.
Archives of general psychiatry 1992;49(7):522-30.
1992: Robert W Buchanan; Brian Kirkpatrick; Ann Summerfelt; Thomas E Hanlon; J Levine; William T Carpenter
Clinical predictors of relapse following neuroleptic withdrawal.
Biological psychiatry 1992;32(1):72-8.
1992: Brian Kirkpatrick; L Alphs; Robert W Buchanan
The concept of supersensitivity psychosis.
The Journal of nervous and mental disease 1992;180(4):265-70.
1992: Alan Breier; Robert W Buchanan
The effects of metabolic stress on plasma progesterone in healthy volunteers and schizophrenic patients.
Life sciences 1992;51(19):1527-34.
1991: William T Carpenter; Robert W Buchanan; Alan Breier; Brian Kirkpatrick; Gunvant K Thaker; Carol A Tamminga
Psychopathology and the question of neurodevelopmental or neurodegenerative disorder.
Schizophrenia research 1991;5(3):192-4.
1991: William T Carpenter; Brian Kirkpatrick; Robert W Buchanan
The new challenges in psychopathology.
Yakubutsu, seishin, kōdō = Japanese journal of psychopharmacology 1991;11(1):95-9.
1991: Alan Breier; O R Davis; Robert W Buchanan
Alprazolam attenuates metabolic stress-induced neuroendocrine and behavioral effects in humans.
Psychopharmacology 1991;104(4):479-84.
1991: William T Carpenter; R Kurz; Brian Kirkpatrick; Thomas E Hanlon; Ann Summerfelt; Robert W Buchanan; Royce Waltrip II; Alan Breier
Carbamazepine maintenance treatment in outpatient schizophrenics.
Archives of general psychiatry 1991;48(1):69-72.
1990: Brian Kirkpatrick; Robert W Buchanan
The neural basis of the deficit syndrome of schizophrenia.
The Journal of nervous and mental disease 1990;178(9):545-55.
1990: William T Carpenter; Thomas E Hanlon; D W Heinrichs; Ann Summerfelt; Brian Kirkpatrick; J Levine; Robert W Buchanan
Continuous versus targeted medication in schizophrenic outpatients: outcome results.
The American journal of psychiatry 1990;147(9):1138-48.
1990: Robert W Buchanan; Brian Kirkpatrick; D W Heinrichs; William T Carpenter
Clinical correlates of the deficit syndrome of schizophrenia.
The American journal of psychiatry 1990;147(3):290-4.
1990: Brian Kirkpatrick; Robert W Buchanan
Anhedonia and the deficit syndrome of schizophrenia.
Psychiatry research 1990;31(1):25-30.
1989: Brian Kirkpatrick; Robert W Buchanan; P D McKenney; L D Alphs; William T Carpenter
The Schedule for the Deficit syndrome: an instrument for research in schizophrenia.
Psychiatry research 1989;30(2):119-23.
1989: Brian Kirkpatrick; William T Carpenter; Robert W Buchanan
Empathy and schizophrenia.
The American journal of psychiatry 1989;146(7):945-6.
1989: Brian Kirkpatrick; Robert W Buchanan; K Maeda; William T Carpenter; D Jauch; Carol A Tamminga
Effect of neuroleptic withdrawal on plasma prolactin: a possible marker of receptor adaptation.
Biological psychiatry 1989;26(2):131-8.
1989: Robert W Buchanan; D W Heinrichs
The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia.
Psychiatry research 1989;27(3):335-50.
1989: Brian Kirkpatrick; Robert W Buchanan; Royce Waltrip II; D Jauch; William T Carpenter
Diazepam treatment of early symptoms of schizophrenic relapse.
The Journal of nervous and mental disease 1989;177(1):52-3.
1989: Gunvant K Thaker; Brian Kirkpatrick; Robert W Buchanan; R Ellsberry; Adrienne C Lahti; Carol A Tamminga
Oculomotor abnormalities and their clinical correlates in schizophrenia.
Psychopharmacology bulletin 1989;25(3):491-7.
1988: D W Heinrichs; Robert W Buchanan
Significance and meaning of neurological signs in schizophrenia.
The American journal of psychiatry 1988;145(1):11-8.